Cook Group

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Lung Stent Market to reach $333.8 million, globally, by 2030 at 7.1% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, February 20, 2024
Boston Scientific, Cook Group, Research, Neoplasm, Traction, Inflammation, Hospital, Quality of life, Stainless steel, Growth, Airway obstruction, Pneumonia, Risk, Chronic obstructive pulmonary disease, Prevalence, Metal, Stent, Patient, Lung cancer, Medtronic, COPD, Uranium mining

The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.

Key Points: 
  • The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.
  • Metal lung stents are expected to dominate the lung stent market in terms of material type.
  • The increasing prevalence of lung diseases, such as lung cancer and pneumonia, is driving the demand for metal lung stents.
  • Tracheobronchial stents and metal lung stents are projected to be the key market opportunities, while North America is expected to dominate the market.

MODEX-The Biggest Manufacturing and Supply Chain Event of 2024 is Coming to Atlanta March 11-14

Retrieved on: 
Monday, February 5, 2024
Technology, Automotive, Machinery, Machine Tools, Metalworking & Metallurgy, Apps, Applications, Other Defense, General Automotive, Other Retail, Entertainment, Other Energy, HVAC, Energy, Other Education, Training, Logistics, Supply Chain Management, Retail, Defense, Education, Women, Consulting, Electronic Commerce, Professional Services, Other Natural Resources, Celebrity, Consumer, Natural Resources, Other Transport, Other Manufacturing, Commercial Building & Real Estate, Trucking, Textiles, Construction & Property, Rail, Steel, Maritime, Packaging, Air, Engineering, Transport, Chemicals, Plastics, Other Technology, Automotive Manufacturing, Aerospace, Software, Manufacturing, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Artificial Intelligence, Partnership, Funding of science, Warehouse, Consultant, Research, Congress Center, Music, Exhibition, Food, Cook Group, EVP, Material, Climate change mitigation, University, Information, MHI, Transformation, WERC, Health, Beer, Wine, Student, Business, Conference, Woman

When the largest manufacturing and supply chain trade event of 2024, MODEX , returns to Atlanta on March 11 it will include over 1,175 exhibitors from leading solution providers and a comprehensive Educational Conference focusing on best-in-class solutions for manufacturing and supply chain operations.

Key Points: 
  • When the largest manufacturing and supply chain trade event of 2024, MODEX , returns to Atlanta on March 11 it will include over 1,175 exhibitors from leading solution providers and a comprehensive Educational Conference focusing on best-in-class solutions for manufacturing and supply chain operations.
  • This event provides attendees to network and connect with young professionals in the material handling and supply chain industry.
  • MODEX is the largest manufacturing and supply chain expo held in North America and South America.
  • MHI is an international trade association that has represented the material handling, logistics and supply chain industry since 1945.

Shore Capital Partners Announces Partnership with C2Dx and Acquisition of Otolaryngology/Head and Neck Surgery Assets from Cook Medical

Retrieved on: 
Wednesday, January 24, 2024
Finance, Surgery, Medical Devices, Health, Professional Services, OHNS, ENT, Partnership, Cook Group, STIC, Acquisition, Dysphagia, Surgeon, Growth, Risk management

Shore Capital Partners (“Shore” or “Shore Capital”) is pleased to announce it has completed a partnership with C2Dx (“C2Dx” or “The Company”), a medical device company based in Kalamazoo, Michigan, with a second location in Memphis, Tennessee.

Key Points: 
  • Shore Capital Partners (“Shore” or “Shore Capital”) is pleased to announce it has completed a partnership with C2Dx (“C2Dx” or “The Company”), a medical device company based in Kalamazoo, Michigan, with a second location in Memphis, Tennessee.
  • Following the partnership, Shore Capital and C2Dx are also pleased to announce they have acquired the Otolaryngology/Head and Neck Surgery (“OHNS”) family of products from Cook Medical (“Cook”).
  • “We are ecstatic to announce our partnership with Shore Capital given their proven playbook for growth and track record of performance, specifically in the medical device space,” Mr. McLeod said.
  • To learn more about partnerships with C2Dx, please visit https://c2dx.com/ , or contact Kevin McLeod ( [email protected] ) or AJ Gauthier ( [email protected] ).

CooperCompanies Expands CooperSurgical’s Medical Device Portfolio with Acquisition of Select Cook Medical® Assets

Retrieved on: 
Wednesday, November 1, 2023
The Cooper Companies, Cook Group, Obstetrics, Acquisition, Surgery, SAN, Cryptocurrency

SAN RAMON, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets.

Key Points: 
  • SAN RAMON, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets.
  • “This acquisition is a fantastic strategic fit for CooperSurgical,” said Al White, President and CEO of CooperCompanies.
  • The acquired assets generated approximately $56 million in trailing twelve-months revenue as of September 30, 2023.
  • Cooper will report these assets as part of its Office and Surgical category within the CooperSurgical business beginning in its fiscal first quarter of 2024.

Frontegg Appoints Enterprise Sales Leader Dane Mustola as Head of Global Sales

Retrieved on: 
Tuesday, October 3, 2023
University, Cook Group, MBA, Okta, Inc., TEL, CIAM, UC, Cornell University, Quantcast, Okta, GTM, Research centers and laboratories at the University of California, Berkeley, Economics, University of California, Santa Barbara, Management, Club

MOUNTAIN VIEW, Calif. and TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Frontegg, the premier customer identity platform, today named Dane Mustola head of global sales, effective immediately. An enterprise sales leader with more than a decade of experience, Mustola will lead Frontegg’s sales team and spearhead the company's GTM strategy across the globe. Mustola and his team are chartered to expand Frontegg and its customer identity management solutions across key vertical markets and geographic regions.

Key Points: 
  • MOUNTAIN VIEW, Calif. and TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Frontegg , the premier customer identity platform, today named Dane Mustola head of global sales, effective immediately.
  • An enterprise sales leader with more than a decade of experience, Mustola will lead Frontegg’s sales team and spearhead the company's GTM strategy across the globe.
  • “I am delighted to join Frontegg as the company’s new head of global sales.
  • My experience within the CIAM category and enterprise-level sales across global brands will lend nicely to CEO Sagi Rodin’s vision for the company,” said head of sales Dale Mustola.

Maravai LifeSciences Announces Appointment of New Director to the Board

Retrieved on: 
Thursday, July 20, 2023
MDIC, Interim, Bard, Melamaravakkadu, Executive, Senior, Doctor of Philosophy, Cook Group, Partner, Biomedical engineering, Nordson Corporation, Science, Organization, Becton, Dickinson and Company headquarters, Injection, Retirement, Acquisition, SAN, Purdue University, Vulnerability and Risk Committee, Management

Dr. DeFord is the Chairman, Chief Executive Officer and President of privately-held, South Carolina-based Samothrace Medical Innovations, Inc., which he co-founded in March 2022.

Key Points: 
  • Dr. DeFord is the Chairman, Chief Executive Officer and President of privately-held, South Carolina-based Samothrace Medical Innovations, Inc., which he co-founded in March 2022.
  • Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners, a venture capital fund.
  • "On behalf of the entire Board, I thank Chip for his valuable perspective and incredible commitment to Maravai over the past six years,” said Carl Hull, Interim Chief Executive Officer and Chairman of the Board.
  • “His numerous contributions and thoughtful insights have been invaluable, and we are grateful for everything he has done for Maravai."

CooperCompanies Announces Second Quarter 2023 Results

Retrieved on: 
Thursday, June 1, 2023
Forecasting, Public expenditure, Rationalization, Cook Group, Loss, Acquisition, GAAP, COVID, Bank statement, Risk management, Bank, Insurance

Details are summarized as follows:

Key Points: 
  • Details are summarized as follows:
    Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022.
  • To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results.
  • We believe it is useful for investors to understand the effects of these items on our consolidated operating results.
  • In addition, our acquisition expenses for the second quarter of 2023 included an accrual for probable payment of a termination fee in connection with an asset purchase agreement.

CooperCompanies Announces First Quarter 2023 Results

Retrieved on: 
Thursday, March 2, 2023
Rationalization, Bank statement, Loss, COVID, GAAP, Forecasting, Public expenditure, Acquisition, Cook Group, Risk management, Bank, Insurance

Details are summarized as follows:

Key Points: 
  • Details are summarized as follows:
    Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022, as the transaction is pending regulatory approval.
  • To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results.
  • We believe it is useful for investors to understand the effects of these items on our consolidated operating results.
  • We exclude the effect of acquisition and integration expenses and the effect of restructuring expenses from our non-GAAP financial results.